The Patent Finder

Hinova Pharmaceuticals Inc.

12 patents currently held · Updated Nov 17, 2026
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
0
Ending by 2030
Dec 2032
Next term end

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 1 fee due Mar 12, 2027
    The maintenance fee for Method for synthesis of deuterated amide and deuterated sulfonamide (US 11,753,392) comes due Mar 12, 2027. Unpaid by Sep 13, 2027, it lapses early.
  • 1 fee due Apr 22, 2027
    The maintenance fee for Quinoline compounds, preparation methods thereof, and uses thereof as urate transporter inhibitor drug (US 10,450,274) comes due Apr 22, 2027. Unpaid by Oct 22, 2027, it lapses early.
  • 1 fee due Aug 6, 2027
    The maintenance fee for Deuterated Defactinib compound and use thereof (US 11,891,379) comes due Aug 6, 2027. Unpaid by Feb 7, 2028, it lapses early.
  • 1 fee due Sep 12, 2027
    The maintenance fee for Halogen-substituted phenylate compound and applications thereof (US 11,926,618) comes due Sep 12, 2027. Unpaid by Mar 13, 2028, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

Nothing was recorded against this company's patents in the last 90 days.

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
PatentTitleStatus Expires Confidence
US 9,346,764Imidazolidinedione compounds and their uses
In force
 · From the USPTO record
In forceFrom the USPTO record
US 9,708,289Imidazole diketone compound and use thereof
In force
 · From the USPTO record
In forceFrom the USPTO record
US 10,450,274Quinoline compounds, preparation methods thereof, and uses thereof as urate transporter inhibitor drug
In force
 · From the USPTO record
In forceFrom the USPTO record
US 11,447,477Indoleamine-2,3-dioxygenase inhibitor, the preparative method and the use thereof
In force
 · From the USPTO record
In forceFrom the USPTO record
US 11,572,371BRD4 Inhibitor
In force
 · High confidence
In forceHigh confidence
US 11,753,392Method for synthesis of deuterated amide and deuterated sulfonamide
In force
 · From the USPTO record
In forceFrom the USPTO record
US 11,591,301Indoleamine-2,3-dioxygenase inhibitor, preparation method therefor and use thereof
In force
 · From the USPTO record
In forceFrom the USPTO record
US 11,926,618Halogen-substituted phenylate compound and applications thereof
In force
 · From the USPTO record
In forceFrom the USPTO record
US 11,891,379Deuterated Defactinib compound and use thereof
In force
 · From the USPTO record
In forceFrom the USPTO record
US 12,194,040FAK inhibitor and drug combination thereof
In force
 · Medium confidence
In forceMedium confidence
10 of 12 patents shown.
Pro members see all 12.
Pro members: see all 12 patents

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

5 pending · 4 abandoned · 8 no status recorded

List them

The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 17, 2026 · includes USPTO assignment data published Nov 16, 2026, status data published Nov 17, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited